Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Page values for "Sumatriptan"

From Pharmacopedia
More actions

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringSumatriptan (succinate)
brandStringImitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC)
structureFile
classesList of String, delimiter: ,[[:Category:Triptans|Triptan (5-HT1B/1D agonist)]] [[:Category:Antimigraine medicines|Antimigraine medicine]] [[:Category:Analgesics|Analgesic]]
mechanismString
usesString'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"'
starting_doseStringOral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours
preparationsStringOral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch)
fda_maxString200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra)
pill_idText
routesList of String, delimiter: ,Oral subcutaneous intranasal
onsetString10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral)
durationString2-4 hours; headache recurrence rate ~20-30% within 24 hours
halflifeString2 hours'"`UNIQ--ref-00000015-QINU`"'
bioavailabilityString~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"'
pregnancyStringLimited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup>
legalString[[USLegal:Prescription only|Rx-only]] in US